Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche says biotech bubble pushes midsize buys out of reach

The biotechnology sector is in a “bubble”, pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday.   “I think this bubble will burst at some point,” Severin Schwan told Reuters in an interview during a visit to London. The Swiss company […]

Read More »

Cannabis drug shows promise in treating schizophrenia

An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial. The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct. The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to […]

Read More »

Analysts bet Novo’s insulin drug will get U.S. green light

Analysts are confident the U.S. Food and Drug Administration (FDA) will soon approve Novo Nordisk’s new long-lasting insulin drug Tresiba — just as they were before the drug was first rebuffed two years ago. Tresiba is considered as a future blockbuster for the Danish company, the Nordic region’s most valuable, but the U.S. regulator asked […]

Read More »

FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug

The U.S. Food and Drug Administration (FDA) advised Waltham, Mass.-based FORUM Pharmaceuticals to halt its clinical trials of encenicline for Alzheimer’s disease yesterday. The FDA cited a small number of serious gastrointestinal (GI) side effects in the studies. As a result, FORUM halted the trial, discontinuing the medication and no new patients will be recruited […]

Read More »

XenoPort’s psoriasis drug found effective; shares jump

Drug developer XenoPort Inc said its experimental drug was effective in treating psoriasis, a chronic inflammatory disease of the skin. XenoPort’s shares jumped 19 percent to $8.00 in premarket trading on Tuesday after the company said the oral drug met the main goal in a mid-stage trial. XenoPort said it expected to start late-stage trials […]

Read More »

Anthera Shares Slump as Zenyaku Kogyo Backs Out of Blisibimod Deal

Hayward, Calif.-based Anthera Pharmaceuticals, Inc. (ANTH) announced today that its Japanese development partner, Zenyaku, had ended a December 2014 Collaboration and License Agreement. The deal will terminate Jan. 7, 2016. The original deal was for the development of blisibimod in Japan. Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine. It […]

Read More »

Sony, Olympus to unveil high-definition endoscope

Sony Corp and Olympus Corp said they plan to unveil an ultra high-definition surgical endoscope this week, the first major product from a joint venture formed three years ago. The product allows physicians to view clearer, more instant images of internal organs, aiding precision during surgical procedures, the medical device makers told Reuters ahead of […]

Read More »

Mylan Begins Hostile Bid for Perrigo

Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances.   Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at about $187 based on Friday’s closing price. Perrigo’s shares […]

Read More »

U.S. bans another Indian drug plant over production quality

The U.S. Food and Drug Administration (FDA) has banned imports from another India-based drug manufacturing plant over quality control concerns, making it the 10th site in the country this year to face such action.   The FDA’s “import alert” on Mumbai-based Polydrug Laboratories Pvt Ltd’s Ambernath manufacturing plant comes two months after Canada banned the […]

Read More »

Raptor Pharma says may stop developing liver drug, shares skid

Raptor Pharmaceutical Corp lost more than a third of its market value after the company said it did not plan to develop its liver drug, which failed to meet the main goal in a second mid-stage study. The company’s shares plunged 35.5 percent to $7.61 in premarket trading on Monday. The study was testing the […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom